Company news
Eisai Co., Ltd. (TSE:4523) news
Eisai Co., Ltd. news releases on 6ix. Latest, Dec 2, 2025: New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms…
Press releases — page 2
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 2, 2025
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
November 30, 2025
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
November 27, 2025
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
November 26, 2025
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
November 25, 2025
Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
November 18, 2025
New data on lecanemab to be presented at CTAD conference
November 17, 2025
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
November 17, 2025
Leqembi® approved for IV maintenance treatment in the United Kingdom
November 13, 2025
IDBS announces i3 2026-An exclusive customer and partner event on data management innovation in BioPharma
November 12, 2025
Sales of Leqembi® totaled 18 billion yen in the third quarter 2025
October 30, 2025
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 29, 2025
Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28, 2025
Health Canada Grants Authorization for Leqembi® (lecanemab)
October 26, 2025
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
October 18, 2025
First patient treated with Leqembi® (lecanemab) in the Nordics
October 14, 2025
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
October 13, 2025
Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
October 6, 2025
Leqembi® approved for the treatment of early Alzheimer's disease in Australia
September 24, 2025
SEED Therapeutics Completes $30 Million Series A-3 Financing
September 23, 2025
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 16, 2025
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
September 8, 2025
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
September 3, 2025
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
September 2, 2025
US FDA approves Leqembi® IQKLIK™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease
August 29, 2025
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
August 29, 2025
Medical Affairs Leader Dr. Kirk Shepard Joins BP Logix’s Life Sciences Strategic Advisory Board
August 26, 2025
Leqembi® (lecanemab) launched in the EU today
August 25, 2025
Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
July 31, 2025
New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
July 30, 2025
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
July 30, 2025
Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
July 22, 2025
EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025
July 21, 2025
Elix Provides AI Drug Discovery Platform "Elix Discovery™" to Eisai
July 17, 2025
The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
July 16, 2025